Kommersiellt obunden läkemedelsinformation riktad till läkare och sjukvårdspersonal


Classification: B

Drug products: Abirateron Avansor, Abirateron Sandoz, Abiraterone Accord, Abiraterone Glenmark, Abiraterone Krka, Abiraterone medac, Abiraterone Mylan, Abiraterone Orion, Abiraterone Qilu, Abiraterone STADA, Abiraterone Zentiva, ZYTIGA

ATC code: L02BX03

Substances: abiraterone, abiraterone acetate


As the substance is only used by men, analyses on sex or gender differences have not been considered relevant.

Additional information

Abiraterone is an inhibitor of 17 alpha-hydroxylase/C17,20-lyase (CYP17) that blocks androgen biosynthesis [1]. The approved indication for abiraterone in combination with methylprednisolone or prednisone is treatment of certain types of prostate cancer [2].

Updated: 2018-12-17

Date of litterature search: 2018-12-06


  1. Physicians' Desk Reference. http://www.pdr.net. [cited 2018-12-06]. länk
  2. Fass.se [cited 2018-12-06]. länk
  3. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2017 [cited 2018-12-06.] länk

Authors: Mia von Euler

Reviewed by: Karin Schenck-Gustafsson

Approved by: Karin Schenck-Gustafsson